Thermogenesis
This article was originally published in The Gray Sheet
Executive Summary
Gains FDA marketing clearance for the automated CryoSeal system for production of cryoprecipitated AHF anti-hemophilic factor, production of which represents a $100 mil. market, according to the company. The firm touts the system's ability to produce AHF on-site within an hour, versus two or three days with traditional manual production. Clinical trials in support of additional indications for producing autologous fibrin glue and autologous platelet derived growth factors will begin in late 1999, Thermogenesis says